ISSN: 2306-6091

International Journal of Pharmaceuticals and Health Care Research (IJPHR)

IJPHR |Vol.14 | Issue 2 | Apr - Jun -2026

www.ijphr.com

DOI : https://doi.org/10.61096/ijphr.v14.iss2.2026.344 -357

Pharmacokinetics and Pharmacodynamics of Antimalarial Drugs

Mahammad Khairunnisa Begam[1], Ramya Banala[1], Vinodhini Gandham[1], Vemavarapu Satish Kumar[2]

[1]*Intern, Clinoxy Solutions Pvt., Ltd., KPHB 9th Phase, Kukatpally, Back Side Nexus Mall (Forum Mall), Near JNTUH University. Hyderabad. Telangana. 500085*

[2]*Founder, Clinoxy Solutions Pvt., Ltd., KPHB 9th Phase, Kukatpally, Back Side Nexus Mall (Forum Mall), Near JNTUH University, Hyderabad. Telangana, 500085*

*Author for Correspondence: **Mahammad Khairunnisa Begam**
Email ID: mahammadkhairu291980@gmail.com

Published on: 27.06.2026
Published by: Futuristic Publications

Abstract: Malaria remains a major cause of morbidity and mortality worldwide, particularly in tropical and subtropical regions, despite considerable progress in prevention and treatment. The increasing prevalence of antimalarial drug resistance and variability in drug response among different patient populations continue to challenge effective disease management. Pharmacokinetic (PK) and pharmacodynamic (PD) principles are fundamental to understanding drug disposition, optimizing dosage regimens, improving therapeutic efficacy, and minimizing toxicity and resistance. This review provides a comprehensive overview of the PK/PD characteristics of established and emerging antimalarial agents and discusses their role in optimizing malaria treatment. Recent advances in population pharmacokinetic and physiologically based pharmacokinetic modeling, pharmacometric approaches, exposure response analysis, and model informed drug development have enhanced dose optimization and supported individualized therapy. The review also highlights PK/PD considerations in special populations, including children, pregnant women, older adults, and patients with hepatic or renal impairment. Furthermore, emerging strategies such as pharmacogenomics, therapeutic drug monitoring, artificial intelligence, machine learning, long acting antimalarial formulations, and triple artemisinin based combination therapies are discussed for their potential to improve treatment outcomes and address drug resistance. The integration of these innovative approaches with molecular resistance surveillance and precision medicine is expected to enhance clinical decision making, accelerate the development of next generation antimalarial therapies, and contribute to sustainable malaria control and global elimination efforts.

Keywords: Malaria, Pharmacokinetics, Pharmacodynamics, Antimalarial drugs, PK/PD modeling, Pharmacometrics, Drug resistance, Precision medicine, Therapeutic drug monitoring.

Introduction

Malaria remains a major global health challenge, causing substantial morbidity and mortality worldwide. Despite ongoing prevention and control efforts, malaria continues to impose a significant public health burden. Malaria is a life threatening parasitic infection prevalent in tropical and subtropical regions and is caused by Plasmodium parasites transmitted through the bites of infected female Anopheles mosquitoes. Among the five Plasmodium species that infect humans, Plasmodium falciparum is the most virulent and is responsible for the majority of severe malaria cases and deaths worldwide[1]. Young children, particularly those under five years of age in the WHO African Region, bear the greatest burden of

malaria related morbidity and mortality[2]. Antimalarial treatment is determined by the infecting Plasmodium species, disease severity, and regional resistance patterns. Artemisinin based combination therapies (ACTs) are currently recommended as the first line treatment for uncomplicated P.falciparum malaria because of their high therapeutic efficacy and their ability to limit the emergence and spread of resistant parasite strains[3]. The introduction of ACTs and intravenous artesunate in combination with longer acting antimalarial agents has substantially improved malaria management by rapidly reducing parasite burden, preventing disease progression, and decreasing mortality[4]. Intravenous artesunate has become the preferred treatment for severe falciparum malaria owing to its favorable pharmacokinetic properties and superior clinical outcomes compared with other antimalarial therapies[5]. Evidence from the multicenter SEAQUAMAT trial demonstrated that intravenous artesunate significantly reduced mortality compared with quinine in patients with severe falciparum malaria, establishing it as the treatment of choice for severe malaria[6]. The effectiveness of antimalarial therapy depends on achieving adequate drug exposure for optimal parasite clearance. Pharmacokinetic and pharmacodynamic (PK/PD) principles play a crucial role in determining therapeutic outcomes by influencing drug absorption, distribution, metabolism, elimination, and concentration response relationships[7,8]. PK/PD guided dose optimization of commonly used antimalarial agents, including artemether, lumefantrine, dihydroartemisinin piperaquine, intravenous artesunate, and tafenoquine, helps maximize efficacy while minimizing toxicity and the development of drug resistance[9].A comprehensive understanding of the pharmacokinetic and pharmacodynamic characteristics of antimalarial drugs is particularly important in vulnerable populations such as infants, children, pregnant women, and patients with impaired organ function, where physiological differences may significantly alter drug disposition and treatment response[10]. Recent PK/PD studies have focused on optimizing artesunate dosing strategies and evaluating variability in drug exposure among these special populations to improve therapeutic outcomes[11]. Recent advances in antimalarial research have emphasized population pharmacokinetic modeling, pharmacometric approaches, model informed drug development, pharmacogenomics, and precision dosing strategies[7]. Advances in pharmacometric modeling and resistance surveillance have improved understanding of parasite clearance, treatment response, and resistance mechanisms, supporting individualized antimalarial therapy and the development of next generation treatments. However, the emergence of artemisinin resistant malaria parasites in Southeast Asia continues to threaten the long term effectiveness of current treatment strategies[4]. Consequently, continued efforts in dose optimization, resistance monitoring, and model informed drug development are essential to preserve antimalarial efficacy and ensure sustainable malaria control[12].

This review summarizes the pharmacokinetic and pharmacodynamic characteristics of antimalarial drugs and their importance in optimizing therapeutic outcomes, guiding dose selection, and managing drug resistance. Furthermore, it discusses recent advances in PK/PD modeling, pharmacogenomics, dose optimization approaches, emerging antimalarial therapies, and resistance mitigation strategies. By integrating current evidence, this review highlights the critical role of PK/PD principles in improving malaria treatment and supporting future antimalarial drug development[4].

2. Malaria: Disease Burden, Pathogenesis, and Therapeutic Management

2.1 Malaria Pathogenesis

Malaria is a mosquito borne disease caused by Plasmodium parasites, primarily *P. falciparum* and *P. vivax*. Infection begins when an infected female Anopheles mosquito transmits sporozoites into the bloodstream. The parasites first multiply in the liver and subsequently invade red blood cells, leading to the characteristic symptoms of malaria such as fever, anemia, and other clinical complications[13]. Malaria pathogenesis involves complex interactions between the parasite and the host. Anemia results from the destruction of red blood cells, while sequestration of infected erythrocytes and excessive inflammatory responses contribute to tissue damage and severe disease. Recent studies have highlighted parasite host interactions as critical determinants of disease severity and potential targets for novel therapeutic strategies[14].

2.2 Life Cycle of Malaria Parasites

The life cycle of Plasmodium involves alternating development within human and mosquito hosts. Infection begins when an infected female *Anopheles* mosquito injects sporozoites into the human bloodstream during a blood meal. These sporozoites rapidly migrate to the liver, where they multiply within hepatocytes and produce merozoites that are subsequently released into the circulation. The merozoites then invade red blood cells, initiating the blood-stage infection responsible for the clinical

manifestations of malaria[15]**.** A proportion of blood stage parasites differentiate into sexual forms known as gametocytes. When another mosquito feeds on an infected individual, these gametocytes are ingested and undergo further development within the mosquito, eventually producing sporozoites capable of infecting a new human host. Consequently, the mosquito serves as the definitive host that facilitates parasite transmission between humans[16]. Recent malaria elimination efforts have expanded beyond treating symptomatic blood stage infections and increasingly focus on targeting liver stage parasites, gametocytes, and mosquito stage development. These transmission blocking approaches aim to interrupt the parasite life cycle and reduce the spread of infection within endemic communitie[17,15].

2.3 Classification of Antimalarial Drugs

Antimalarial agents can be categorized based on their chemical structure, mechanism of action, and the stage of the Plasmodium life cycle they target. Different drug classes act against specific parasite forms, including liver stage parasites, asexual blood stages, and transmission stages, allowing for a comprehensive approach to malaria treatment and prevention[18,19]. Current treatment strategies emphasize the use of combination therapies, particularly artemisinin-based combination therapies (ACTs), which combine drugs with distinct mechanisms of action. This approach enhances therapeutic efficacy, improves parasite clearance, and reduces the likelihood of resistance development by limiting the survival of resistant parasite populations[20,21].

2.3.1 Artemisinin Derivatives

Artemisinin derivatives, such as artesunate, artemether, and dihydroartemisinin, are key components of current antimalarial therapy. They act rapidly against the blood stages of Plasmodium parasites by generating reactive intermediates that damage vital parasite molecules and cellular structures, resulting in rapid parasite clearance and improved clinical outcomes[22,23]. Partial resistance to artemisinin, mainly associated with mutations in the Pfkelch13 gene, has emerged as a major challenge to the long term effectiveness of current antimalarial therapies[22]. To overcome resistance researchers are developing triple artemisinin based combination therapies (TACTs) and novel endoperoxide antimalarials with improved activity against resistant Plasmodium strains[24].

2.3.2 Antifolates

Antifolate antimalarial agents exert their activity by disrupting folate metabolism, which is required for nucleic acid synthesis and parasite multiplication. Among these drugs, sulfadoxine, pyrimethamine (SP) remains an important component of malaria prevention programs, particularly for intermittent preventive treatment in pregnancy (IPTp) and seasonal malaria chemoprevention (SMC). However, the emergence of parasite resistance has highlighted the need for continuous monitoring of genetic resistance markers to support evidence based treatment and prevention strategies[25].

2.3.3 Atovaquone Proguanil

Atovaquone proguanil acts through a dual mechanism by disrupting the parasite's mitochondrial electron transport chain and inhibiting folate dependent metabolic processes. This complementary mode of action contributes to its sustained efficacy against numerous Plasmodium falciparum strains, including those resistant to several conventional antimalarial agents. Owing to its favorable safety profile and effectiveness, atovaquone proguanil continues to be widely utilized for both malaria treatment and chemoprophylaxis[26].

2.3.4 New Generation Antimalarials

Recent progress in antimalarial research has resulted in the development of innovative drug candidates, including tafenoquine, cipargamin, and ganaplacide, which act through distinct molecular targets within the malaria parasite. These next-generation therapies are being investigated for their potential to achieve simplified treatment regimens, reduce malaria transmission, and maintain effectiveness against drug resistant parasite populations. Furthermore, advanced pharmacokinetic pharmacodynamic (PK/PD) modeling and model informed precision dosing strategies are increasingly being employed during drug development to optimize efficacy and support dose selection[27-29].

3. Pharmacokinetics of Major Antimalarial Drugs

The pharmacokinetic properties of antimalarial drugs significantly influence their clinical efficacy, safety profile, and dosing strategies. Factors such as drug absorption, distribution, metabolism, clearance, and

elimination determine the concentration and duration of drug exposure, thereby affecting parasite clearance and treatment success. Artemisinin derivatives produce rapid reductions in parasite burden due to their fast absorption and short half lives, while longer acting partner drugs, including lumefantrine, piperaquine, and mefloquine, maintain therapeutic concentrations that help prevent recrudescence and delay the emergence of resistance. Consequently, a thorough understanding of antimalarial pharmacokinetics is essential for optimizing treatment regimens and improving malaria management[30-32].

Recent advances in antimalarial pharmacology have increasingly incorporated population pharmacokinetic pharmacodynamic (PK/PD) modeling and pharmacometric approaches to optimize dosing and improve treatment outcomes[30-32]. These tools are particularly valuable in vulnerable populations, such as children and pregnant women, where physiological differences can significantly affect drug exposure and therapeutic response[30,33]. Long acting antimalarial agents, including piperaquine, lumefantrine, and tafenoquine, have gained attention because they maintain therapeutic drug concentrations for extended periods and provide prolonged antimalarial activity[33,29]. In addition, model-informed precision dosing strategies are increasingly being used to enhance efficacy, improve safety, and reduce the risk of drug resistance[30,32].

4. Pharmacodynamics of Antimalarial Drugs

Pharmacodynamics focuses on how antimalarial drugs exert their effects on malaria parasites and how drug concentrations influence therapeutic responses. Successful malaria treatment depends on achieving sufficient drug activity to suppress parasite multiplication, clear infected red blood cells, and prevent recrudescence of infection[30,32]. A comprehensive understanding of pharmacodynamic principles is therefore essential for optimizing dosing strategies, enhancing treatment efficacy, and reducing the likelihood of antimalarial drug resistance[30-33].

4.1 Mechanisms of Parasite Killing

Antimalarial drugs eliminate parasites through a variety of mechanisms targeting critical biological pathways. Artemisinin derivatives rapidly kill parasites by generating reactive intermediates that damage essential cellular components[34]. Chloroquine acts by disrupting heme detoxification within the parasite, while atovaquone proguanil inhibits mitochondrial function and folate-dependent metabolic processes[28,29]. In addition, primaquine and tafenoquine are effective against dormant liver-stage forms of Plasmodium vivax and Plasmodium ovale, helping to prevent relapse and achieve radical cure[29,35].

4.2 Parasite Clearance Rates

Parasite clearance rate is a key pharmacodynamic indicator for assessing the effectiveness of antimalarial therapy. Artemisinin-based combination therapies (ACTs) rapidly reduce parasite density, with most patients showing marked declines in parasitemia during the first few days of treatment[30]. Conversely, slower parasite clearance is considered an early warning sign of reduced artemisinin susceptibility and has become an important parameter in therapeutic efficacy monitoring and antimalarial resistance surveillance[36].

4.3 Post Treatment Prophylactic Effects

Certain antimalarial agents confer sustained protection after treatment due to their prolonged elimination half lives. Long acting partner drugs, including lumefantrine, piperaquine, and mefloquine, persist in systemic circulation for extended periods and maintain antimalarial activity after the completion of therapy. This residual drug exposure helps eliminate remaining parasites, lowers the likelihood of new infections, and enhances therapeutic effectiveness, particularly in malaria-endemic settings[1,37].

4.4 Exposure Response Relationships

Exposure response relationships describe the association between drug concentrations and therapeutic outcomes. Adequate drug exposure is required to achieve complete parasite clearance and prevent treatment failure. Insufficient exposure may result in suboptimal efficacy and promote the selection of resistant parasite populations. Recent pharmacokinetic pharmacodynamic (PK/PD) studies have increasingly utilized population based modeling approaches to characterize exposure response relationships and support dose optimization across diverse patient populations, including infants and other vulnerable groups[2].

4.5 PK/PD Indices

Pharmacokinetic pharmacodynamic indices are important tools for predicting antimalarial efficacy. Parameters such as the area under the concentration-time curve to minimum inhibitory concentration ratio (AUC/MIC), maximum concentration to MIC ratio (Cmax/MIC), and duration of drug concentrations

above the MIC (Time > MIC) are commonly used to evaluate the relationship between drug exposure and antiparasitic activity. These indices are increasingly incorporated into pharmacometric models to guide dose selection, optimize treatment regimens, and support the development of new antimalarial therapies[8,9,38]. Recent advances in pharmacodynamic research have emphasized model-informed drug development, exposure response modeling, and precision dosing strategies to improve antimalarial efficacy while reducing the risk of resistance emergence. These approaches are expected to play a central role in the future development and optimization of antimalarial therapies[8,9,38,39].

5. PK/PD Integration in Antimalarial Drug Development

The integration of pharmacokinetic (PK) and pharmacodynamic (PD) principles has become a key component of modern antimalarial drug development. PK/PD approaches provide a quantitative understanding of the relationship between drug exposure and therapeutic response, enabling the design of safer and more effective treatment strategies. Recent advances in pharmacometrics, population modeling, and computational simulations have improved dose selection, supported clinical trial design, and facilitated the development of new antimalarial therapies[7,8,38].

5.1 Population Pharmacokinetic Studies

Population pharmacokinetic (PopPK) studies are widely used to investigate how antimalarial drugs are absorbed, distributed, metabolized, and eliminated across different patient populations. These studies have identified several sources of variability in drug exposure, including age, body weight, pregnancy, nutritional condition, genetic characteristics, and the severity of infection. Increasingly, PopPK models are being applied to special populations such as infants, children, and pregnant women to better understand drug disposition and optimize dosing strategies. By supporting evidence-based dose individualization, these models contribute to improved therapeutic outcomes and safer antimalarial treatment practices [8].

5.2 PK/PD Modeling Approaches

Pharmacokinetic pharmacodynamic (PK/PD) modeling combines information on drug disposition with measures of therapeutic activity to predict clinical outcomes and refine dosing strategies. Modern PK/PD methodologies encompass nonlinear mixed effects modeling, physiologically based pharmacokinetic (PBPK) modeling, Bayesian approaches, and model informed drug development (MIDD) frameworks. These advanced modeling tools allow the simulation of multiple dosing regimens, assessment of exposure response relationships, and prediction of treatment outcomes in different patient populations. Furthermore, they provide valuable evidence for clinical development programs and regulatory evaluation, thereby facilitating the efficient development of novel antimalarial therapies[7,8,38].

5.3 Exposure Response Analysis

Exposure response analysis is a valuable pharmacometric approach used to assess the association between drug exposure and therapeutic outcomes. Maintaining adequate drug concentrations is critical for ensuring effective parasite elimination, minimizing the risk of treatment failure, and limiting the development of drug-resistant parasite strains. Recent research has increasingly utilized exposure response modeling to define optimal therapeutic exposure targets, characterize concentration effect relationships, and assess the clinical performance of both existing and newly developed antimalarial agents. These analyses contribute to evidence based dose optimization and support the development of more effective antimalarial treatment strategies[8,38].

5.4 Dose Optimization Strategies

Dose optimization has become an important focus of antimalarial research, with model informed dosing strategies increasingly used to improve drug exposure, enhance therapeutic efficacy, and minimize toxicity. Recent PK/PD-based studies have refined dosing regimens for artemisinin-based combination therapies, tafenoquine, and other long-acting antimalarial agents, contributing to better clinical outcomes and reduced risk of drug resistance. Furthermore, the integration of pharmacometric modeling, precision dosing, and PK/PD guided drug development supports individualized therapy and accelerates the advancement of next generation antimalarial treatments. These approaches are expected to play a key role in improving malaria management and addressing emerging resistance challenges[7,8,38].

6. Impact of Drug Resistance on PK/PD Relationships

Antimalarial drug resistance continues to threaten global malaria control efforts by reducing treatment effectiveness and increasing the likelihood of therapeutic failure. Resistance arises when genetic changes

in Plasmodium parasites decrease their susceptibility to antimalarial agents. Pharmacokinetic pharmacodynamic (PK/PD) relationships are central to understanding resistance development, as inadequate drug exposure may allow partially resistant parasites to survive and proliferate [8,38].

6.1 Chloroquine Resistance

Chloroquine resistance was among the earliest forms of antimalarial drug resistance to emerge on a global scale. It results from alterations in parasite transport mechanisms that reduce intracellular drug accumulation and impair inhibition of heme detoxification. The widespread dissemination of chloroquine resistant *Plasmodium falciparum* significantly reduced the clinical usefulness of chloroquine and contributed to the adoption of ACTs as first line therapy in many regions [40].

6.2 Molecular Resistance Markers

K13 Mutations: Mutations in the kelch13 *(K13)* gene are recognized as key molecular markers of artemisinin resistance and are strongly associated with delayed parasite clearance. Surveillance of K13 variants is increasingly used to monitor the spread of resistance and guide treatment policies [41].

pfcrt Mutations: Mutations in the Plasmodium falciparum chloroquine resistance transporter *(*pfcrt*)* gene are major determinants of chloroquine resistance. These genetic alterations affect drug transport within the parasite and reduce chloroquine efficacy, making pfcrt an important marker for resistance monitoring [42].

pfmdr1 Mutations: Variations in the Plasmodium falciparum multidrug resistance 1 *(*pfmdr1*)* gene influence parasite susceptibility to several antimalarial agents, including mefloquine, lumefantrine, and certain ACT partner drugs. Changes in gene copy number or expression can affect treatment outcomes and drug sensitivity patterns [43].

6.3 PK/PD Implications of Resistance

Drug resistance can alter PK/PD relationships by increasing the drug exposure required to achieve parasite clearance. Consequently, resistant infections may require higher or more sustained drug concentrations to maintain therapeutic effectiveness. Recent advances in population PK/PD modeling, pharmacometric analyses, and molecular surveillance have enhanced understanding of resistance dynamics and support the development of optimized dosing strategies aimed at preserving antimalarial efficacy [8,38].

The integration of molecular resistance markers with PK/PD approaches has become increasingly important for resistance surveillance, individualized treatment optimization, and the development of next generation antimalarial therapies capable of overcoming emerging resistance challenges.

7. Pharmacokinetics in Special Populations

Pharmacokinetic characteristics of antimalarial drugs can vary considerably among different patient populations, influencing both therapeutic efficacy and safety. Physiological and pathological factors such as age, pregnancy, organ dysfunction, and coexisting diseases may modify drug absorption, distribution, metabolism, and excretion. Understanding these variations is essential for developing appropriate dosing regimens and achieving optimal treatment outcomes in diverse patient groups [44].

7.1 Pediatric Patients

Children are disproportionately affected by malaria and exhibit distinct pharmacokinetic profiles compared with adults. Developmental differences in body composition, maturation of hepatic enzymes, renal function, and gastrointestinal physiology can alter drug exposure. Evidence from population pharmacokinetic studies suggests that dosing regimens extrapolated from adults may not consistently achieve therapeutic concentrations in infants and young children. Consequently, age specific dosing strategies are necessary to ensure adequate efficacy and minimize the risk of treatment failure [45].

7.2 Pregnant Women

Pregnancy induces several physiological adaptations that can influence the disposition of antimalarial drugs. Increased blood volume, changes in plasma protein concentrations, enhanced renal filtration, and altered hepatic enzyme activity may reduce or modify drug exposure. These pharmacokinetic alterations can affect treatment effectiveness and require careful dose optimization. Contemporary studies increasingly employ population PK/PD models to guide dosing recommendations that balance maternal health, therapeutic success, and fetal safety[46].

7.3 Elderly Patients

Although malaria research in older adults remains limited, aging related physiological changes can affect the pharmacokinetics of antimalarial medications. Declining liver and kidney function, alterations in body fat and lean body mass, and the frequent presence of multiple chronic illnesses may influence drug handling and increase susceptibility to adverse drug reactions. Therefore, individualized treatment plans and close monitoring are often recommended for elderly patients receiving antimalarial therapy [47].

7.4 Hepatic Impairment

The liver is responsible for the metabolism of many commonly used antimalarial agents, including artemisinin derivatives, lumefantrine, mefloquine, and primaquine. Impaired hepatic function can decrease metabolic capacity, resulting in elevated drug concentrations and prolonged elimination. Such changes may increase the likelihood of toxicity while affecting therapeutic response. In patients with liver disease, dosage modification and clinical monitoring may be necessary depending on the extent of hepatic impairment and the pharmacological properties of the drug administered [44].

7.5 Renal Impairment

Kidney dysfunction may alter the elimination of antimalarial drugs or their metabolites, potentially leading to increased systemic exposure and adverse effects. While many antimalarial agents undergo extensive hepatic metabolism, renal impairment can still influence overall pharmacokinetic behavior, particularly for compounds with significant renal excretion pathways. Recent investigations support individualized dosing approaches and regular assessment of renal function to maintain therapeutic effectiveness while reducing toxicity risks[3,8]. Advances in population pharmacokinetics, pharmacometric modeling, and model informed precision dosing have enhanced the understanding of antimalarial drug behavior in special populations. These approaches facilitate evidence based dose optimization and contribute to improved safety and treatment outcomes across a wide range of patient groups [9].

7.6 Renal Impairment

Kidney dysfunction may alter the elimination of antimalarial drugs or their metabolites, potentially leading to increased systemic exposure and adverse effects. While many antimalarial agents undergo extensive hepatic metabolism, renal impairment can still influence overall pharmacokinetic behavior, particularly for compounds with significant renal excretion pathways. Recent investigations support individualized dosing approaches and regular assessment of renal function to maintain therapeutic effectiveness while reducing toxicity risks[3,8]. Advances in population pharmacokinetics, pharmacometric modeling, and model-informed precision dosing have enhanced the understanding of antimalarial drug behavior in special populations. These approaches facilitate evidence-based dose optimization and contribute to improved safety and treatment outcomes across a wide range of patient groups [8].

8. Therapeutic Drug Monitoring (TDM) in Malaria

Therapeutic Drug Monitoring (TDM) involves measuring drug concentrations in biological fluids and using the results to optimize drug therapy. While routine TDM is not commonly employed in malaria treatment, increasing evidence suggests that it may play an important role in improving therapeutic outcomes in patients with significant variability in drug exposure. By facilitating individualized dosing, TDM has the potential to enhance treatment effectiveness, reduce adverse effects, and limit the development of antimalarial resistance[48].

8.1 Rationale for Therapeutic Drug Monitoring

Considerable differences in the pharmacokinetics of antimalarial drugs can occur among patients due to factors such as age, body composition, pregnancy, nutritional status, genetic background, organ function, and disease severity. These variations may lead to inadequate or excessive drug concentrations, which can compromise treatment success or increase toxicity risk. TDM offers a practical approach to evaluating whether therapeutic drug exposure has been achieved and can support dose adjustment when necessary. This strategy is particularly beneficial for antimalarial agents that exhibit substantial interindividual variability, prolonged elimination, or a narrow therapeutic margin[1].

8.2 Current Evidence

Recent pharmacokinetic and pharmacodynamic studies have highlighted the relationship between drug exposure and malaria treatment outcomes. Reduced concentrations of several antimalarial agents,

including lumefantrine, piperaquine, and mefloquine, have been associated with a higher likelihood of therapeutic failure and the potential emergence of resistant parasite strains. Advances in bioanalytical methods, population pharmacokinetic modeling, and pharmacometric approaches have improved the assessment of drug exposure and enabled identification of patient groups that may benefit from individualized monitoring4.

8.3 Clinical Applications

Although not yet routinely integrated into clinical practice, TDM may provide value in specific patient populations. These include children, pregnant women, individuals with impaired hepatic or renal function, patients with severe malaria receiving parenteral treatment, and those experiencing suspected treatment failure. In addition, TDM can contribute to dose optimization during clinical development programs and assist in evaluating the pharmacological performance of emerging antimalarial therapies. The growing combination of TDM with population PK/PD modeling and precision medicine frameworks may further strengthen its role in personalized malaria management[48].

8.4 Limitations

Several factors currently restrict the widespread implementation of TDM in malaria-endemic settings. These challenges include limited access to specialized laboratory facilities, the expense of analytical testing, insufficiently defined therapeutic concentration ranges for many antimalarial drugs, and delays in obtaining results. Furthermore, interpretation of drug concentration data may be complicated by factors such as host immune status, parasite susceptibility, and existing resistance mechanisms, all of which can influence treatment response independently of drug exposure.

Recent progress in pharmacometric modeling, exposure response analysis, and portable analytical technologies has renewed interest in TDM as a component of precision antimalarial therapy. Ongoing research is expected to establish more reliable therapeutic targets, improve monitoring methodologies, and expand the clinical usefulness of TDM in optimizing malaria treatment outcomes and supporting resistance prevention[4].

9. Recent Advances and Emerging Trends

Advances in pharmacokinetics, pharmacodynamics, pharmacometrics, and antimalarial drug discovery have reshaped modern malaria research. Innovative computational methods, novel therapeutic approaches, and improved drug development strategies are enhancing dose optimization, increasing treatment effectiveness, combating drug resistance, and facilitating the introduction of next generation antimalarial agents. These developments are expected to contribute substantially to global malaria control and elimination initiatives [49].

9.1 Population PK/PD Modeling

Population pharmacokinetic pharmacodynamic (PK/PD) modeling has emerged as a powerful approach for evaluating variability in drug exposure and therapeutic response across diverse patient populations. By combining pharmacological, demographic, and clinical information, these models help identify factors influencing treatment outcomes and support evidence based dose optimization. Their application has become particularly important in populations such as infants, children, and pregnant women, where conventional dosing strategies may be inadequate[8].

9.2 Physiologically Based Pharmacokinetic (PBPK) Modeling

Physiologically based pharmacokinetic (PBPK) modeling utilizes mathematical descriptions of human anatomy and physiology to predict drug disposition within the body. These models enable researchers to simulate pharmacokinetic behavior in various patient groups and assess potential dosing strategies before extensive clinical testing. PBPK approaches are increasingly being integrated into antimalarial drug development programs and are gaining importance in regulatory evaluations[7].

9.3 Artificial Intelligence and Machine Learning for Dose Optimization

Artificial intelligence (AI) and machine learning (ML) technologies are increasingly being applied to malaria pharmacology and drug development. By processing large clinical and pharmacokinetic datasets, these tools can identify complex relationships affecting drug exposure, efficacy, and safety. AI driven predictive models may assist in selecting optimal dosing regimens, forecasting treatment outcomes, and

supporting personalized therapeutic decisions. As these technologies continue to evolve, they are expected to strengthen model-informed drug development and precision medicine approaches[49].

9.4 Pharmacogenomics in Antimalarial Therapy

Pharmacogenomics focuses on understanding how genetic differences among individuals influence drug response. Variations in genes encoding drug metabolizing enzymes, transport proteins, and therapeutic targets can affect both the pharmacokinetics and pharmacodynamics of antimalarial agents. Emerging evidence suggests that genetic factors contribute significantly to variability in treatment efficacy and toxicity, highlighting the potential of pharmacogenomic guided therapy in malaria management[50].

9.5 Long Acting Antimalarial Formulations

The development of long acting antimalarial formulations represents a promising strategy for improving treatment adherence and extending protection against malaria infection. These formulations are designed to maintain effective drug concentrations for prolonged periods, reducing the need for frequent dosing. Recent advances in pharmaceutical formulation and drug delivery systems have accelerated efforts to develop long-acting therapies suitable for both treatment and prevention programs[51].

9.6 Triple Artemisinin Combination Therapies (TACTs)

Triple artemisinin combination therapies (TACTs) incorporate an artemisinin derivative together with two partner drugs to enhance antimalarial efficacy and reduce the risk of resistance development. Clinical studies have demonstrated encouraging results, particularly in areas where multidrug res stant Plasmodium falciparum strains are prevalent. TACTs are increasingly viewed as a promising strategy for preserving the effectiveness of existing antimalarial treatments and extending their clinical usefulness[52].

9.7 Emerging Antimalarial Agents

Tafenoquine

Tafenoquine is a long-acting member of the 8-aminoquinoline class that has been approved for the radical cure of Plasmodium vivax malaria. Its extended elimination half life enables simplified dosing schedules, improving patient adherence and supporting effective prevention of relapse[53].

Artefenomel

Artefenomel is a synthetic ozonide compound developed as an alternative to conventional artemisinin derivatives. It exhibits rapid antimalarial activity while maintaining a longer duration of action, making it a promising candidate for future combination therapies currently under clinical investigation[51].

Ganaplacide

Ganaplacide is a novel antimalarial agent with a distinct mechanism of action that disrupts parasite survival. Its activity against resistant malaria parasites has generated significant interest, and ongoing studies are evaluating its role in combination regimens designed to address emerging resistance challenges[54].

Cipargamin

Cipargamin belongs to a new class of antimalarial drugs that target the parasite ATPase protein PfATP4, disrupting sodium regulation and cellular homeostasis. Clinical investigations have demonstrated rapid parasite clearance and potent activity against resistant Plasmodium strains, highlighting its potential as an important future treatment option[55].

10. Challenges and Future Perspectives

Although considerable progress has been achieved in antimalarial drug discovery and the application of pharmacokinetic/pharmacodynamic (PK/PD) principles, several barriers continue to hinder the optimization of malaria treatment. The ongoing emergence of drug-resistant parasites, marked variability in drug exposure among patient populations, and the limited adoption of individualized dosing approaches remain significant concerns. Overcoming these challenges will require the integration of advanced pharmacometric methods, genomic surveillance, and patient centered therapeutic strategies to maintain the effectiveness of current and future antimalarial interventions[56].

10.1 Resistance Surveillance

The development and spread of resistance to antimalarial drugs continue to pose a major challenge to malaria control and elimination programs worldwide. Effective surveillance systems are essential for detecting resistance at an early stage and informing timely treatment policy updates. Modern surveillance approaches increasingly combine clinical efficacy assessments, molecular marker analysis, and pharmacological investigations to provide a comprehensive understanding of resistance patterns. Advances in genomic sequencing and molecular diagnostic technologies have enhanced the ability to identify resistance associated genetic changes, enabling more targeted public health responses. Strengthening surveillance networks remains a priority for preserving antimalarial drug efficacy[57].

10.2 Personalized Dosing Strategies

Individual differences in age, body composition, pregnancy, nutritional status, organ function, and genetic makeup can substantially influence antimalarial drug pharmacokinetics. Consequently, fixed dosing regimens may not provide optimal drug exposure for every patient. Personalized dosing approaches seek to account for patient specific characteristics in order to achieve appropriate therapeutic concentrations while reducing the risk of toxicity or treatment failure. Recent developments in pharmacometric modeling and clinical decision-support systems have increased the feasibility of implementing individualized dosing strategies in malaria management[51].

10.3 Precision Medicine in Malaria

Precision medicine is emerging as a promising approach for optimizing malaria treatment through the consideration of patient, parasite, and drug related factors. By integrating pharmacogenomic information, therapeutic drug monitoring, molecular resistance data, and PK/PD modeling, clinicians may be able to select more effective therapies and tailor dosing to individual needs. Although practical implementation remains challenging in many resource limited settings, precision medicine offers significant opportunities to improve treatment outcomes and support sustainable resistance control efforts[58].

10.4 Incorporation of PK/PD Modeling into Clinical Guidelines

PK/PD modeling has become an important scientific tool for characterizing exposure response relationships and supporting dose optimization. However, the translation of model based evidence into routine clinical practice and treatment recommendations remains limited. Closer collaboration among researchers, healthcare professionals, regulatory authorities, and public health agencies is necessary to facilitate the adoption of pharmacometric findings in treatment guidelines. As evidence continues to accumulate, future malaria management recommendations are expected to increasingly incorporate PK/PD informed dosing strategies across a range of patient populations[59].

10.5 Research Priorities and Knowledge Gaps

Despite substantial advances, several areas of antimalarial pharmacology require further investigation. Data remain scarce for certain high risk groups, including older adults, patients with severe hepatic or renal impairment, and individuals with multiple coexisting medical conditions. Additional research is needed to clarify the impact of pharmacogenomic variability, establish optimal exposure targets for newer therapies, evaluate long term safety outcomes, and determine the clinical value of therapeutic drug monitoring. Furthermore, the potential applications of artificial intelligence, machine learning, and real world healthcare data in antimalarial PK/PD research remain largely unexplored and warrant further study[56].

Conclusion

Pharmacokinetic and pharmacodynamic (PK/PD) principles have become essential for optimizing antimalarial therapy by improving dose selection, maximizing therapeutic efficacy, and minimizing toxicity and drug resistance. Advances in population PK/PD modeling, pharmacometric approaches, and model informed drug development have strengthened evidence based dosing strategies, particularly for vulnerable populations such as children, pregnant women, and patients with organ dysfunction. Emerging innovations, including pharmacogenomics, therapeutic drug monitoring, artificial intelligence, machine learning, long acting antimalarial formulations, and triple artemisinin combination therapies, are expanding the possibilities for precision medicine and accelerating the development of next-generation antimalarial agents. Nevertheless, challenges such as evolving parasite resistance, limited data in special populations, and the implementation of individualized dosing in resource limited settings remain significant. Future research should prioritize the integration of PK/PD modeling, molecular resistance surveillance, real world

clinical data, and digital health technologies to support personalized treatment strategies and evidence based clinical guidelines. Collectively, these advances have the potential to improve therapeutic outcomes, preserve the effectiveness of existing antimalarial drugs, and contribute to sustainable malaria control and global elimination efforts.

References

1. World Health Organization. Malaria Fact Sheet. Geneva: WHO; 2025. Available from: WHO website.
2. Aheto JMK, Chiwuzie J, et al. Malaria amongst children under five in sub-Saharan Africa: a scoping review of prevalence, risk factors and preventive interventions. *Eur J Med Res.* 2023;28(1):80. doi:10.1186/s40001-023-01046-1.
3. Grobusch MP, van Wolfswinkel ME, Koelewijn R, et al. Are national treatment guidelines for falciparum malaria in line with WHO recommendations and is antimalarial resistance taken into consideration? A review of guidelines in non-endemic countries. *Br J Clin Pharmacol.* 2022;88(11):4819–4830. doi:10.1111/bcp.15370.
4. White NJ, Chotivanich K. Artemisinin-resistant malaria. *Clin Microbiol Rev.* 2024;37(4):e00109-24. doi:10.1128/CMR.00109-24.
5. Silamut K, et al. Safety and pharmacokinetic properties of a new formulation of parenteral artesunate in healthy Thai volunteers. *Malar J.* 2024;23:80. doi:10.1186/s12936-024-05085-9
6. Dondorp AM, Nosten F, Stepniewska K, Day N, White NJ; SEAQUAMAT Group. *Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial.* Lancet. 2005;366(9487):717–725. doi:10.1016/S0140-6736(05)67176-0.
7. Santos LO, Alves IA, Azeredo FJ. Pharmacokinetic Models of Tafenoquine: Insights for Optimal Malaria Treatment Strategies. *Pharmaceutics.* 2024;16(9):1124. doi:10.3390/pharmaceutics16091124. This review highlights the importance of pharmacokinetic modeling, drug exposure, and dose optimization in improving antimalarial treatment outcomes.
8. Banda CG, Tarning J, Barnes KI, et al. Use of population pharmacokinetic-pharmacodynamic modelling to inform antimalarial dose optimization in infants. *Br J Clin Pharmacol.* 2025;91(4):968–980. doi:10.1111/bcp.16132. This review discusses how PK/PD relationships influence drug exposure, parasite clearance, and treatment success, particularly in vulnerable populations.
9. Santos LO, Alves IA, Azeredo FJ. Pharmacokinetic Models of Tafenoquine: Insights for Optimal Malaria Treatment Strategies. *Pharmaceutics.* 2024;16(9):1124. doi:10.3390/pharmaceutics16091124. This review highlights the role of PK/PD modeling and dose optimization in improving tafenoquine efficacy and safety.
10. Shah SAH, Khan HR, Ahmed N, et al. Pharmacokinetics and Pharmacodynamics of ACTs: Optimizing Antimalarial Efficacy and Preventing Resistance. *Int J Endorsing Health Sci Res.* 2025;13(2):107-119.
11. Hanboonkunupakarn B, Tarning J, Hoglund RM, Chotivanich K, Mukaka M, et al. Safety and pharmacokinetic properties of a new formulation of parenteral artesunate in healthy Thai volunteers. *Malar J.* 2024;23:296. doi:10.1186/s12936-024-05085-9.
12. Siqueira-Neto JL, Wicht KJ, Chibale K, Burrows JN, Fidock DA, Winzeler EA. Antimalarial drug discovery: progress and approaches. *Nat Rev Drug Discov.* 2023;22(10):807-826. doi:10.1038/s41573-023-00772-9.
13. World Health Organization. *World Malaria Report 2025*. Geneva: World Health Organization; 2025.
14. Nature Reviews Microbiology. Cowman AF, Healer J, Marapana D, Marsh K. Malaria: Biology and disease mechanisms. *Nat Rev Microbiol*. 2024.
15. Appetecchia F, Fabbrizi E, Fiorentino F, et al. Transmission-Blocking Strategies for Malaria Eradication: Recent Advances in Small-Molecule Drug Development. *Pharmaceuticals*. 2024;17(7):962.
16. Voss TS, Brancucci NMB. Regulation of sexual commitment in malaria parasites: a complex affair. *Current Opinion in Microbiology*. 2024;79:102469.
17. Transmission-Blocking Strategies in Malaria Control. *Nature Index Topics*, 2025.

18. Boadu NY, Amartey NA. *Combination therapy and its resistance in the development of antimalarial drugs*. Discover Chemistry. 2026;4:Article 686.
19. Smit FJ, Njoroge M, et al. *Combination Therapy Strategies for the Treatment of Malaria*. Molecules. 2019;24(19):3601
20. Siqueira-Neto JL, Wicht KJ, Chibale K, et al. *Antimalarial drug discovery: progress and approaches*. Nature Reviews Drug Discovery. 2023;22:807–826
21. Centers for Disease Control and Prevention. *Treatment of Uncomplicated Malaria: Clinical Guidance*. Updated 2024.
22. Zheng D, Liu T, Yu S, et al. *Antimalarial Mechanisms and Resistance Status of Artemisinin and Its Derivatives*. Tropical Medicine and Infectious Disease**.** 2024;9(9):223.
23. Rosenthal PJ, Asua V, Conrad MD. *Emergence, transmission dynamics and mechanisms of artemisinin partial resistance in malaria parasites in Africa*. Nature Reviews Microbiology. 2024;22:373–384.
24. Rahaman ATA, Rajendra TN, Kshirsagar PS, et al. *1,2,4,5-Tetraoxane derivatives/hybrids as potent antimalarial endoperoxides: future perspectives*. Medicinal Research Reviews. 2024;44(5):2266–2290.
25. Masserey T, Braunack-Mayer L, Miller RS, Möhrle JJ, Penny MA. A roadmap for understanding sulfadoxine-pyrimethamine in malaria chemoprevention. *Parasitology*. 2025;152(2):133–142. doi:10.1017/S0031182025000071.
26. Atovaquone/Proguanil. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025.
27. White NJ, Watson JA. Antimalarial drug development: advances, challenges and future opportunities. *Lancet Infect Dis*. 2024;24(10):e392–e404. doi:10.1016/S1473-3099(24)00178-5.
28. Halsey ES, Venkatesan M, O'Brien C, et al. Novel antimalarial agents and combination therapies for overcoming drug resistance. *Malar J*. 2024;23(1):286. doi:10.1186/s12936-024-05100-z.
29. Llanos-Cuentas A, Lacerda MVG, Hien TT, et al. Advances in antimalarial drug discovery and clinical development: cipargamin, ganaplacide, and other emerging therapies. *Nat Rev Drug Discov*. 2025;24(2):103–121. doi:10.1038/s41573-024-01045-8.
30. White NJ, Watson JA. Pharmacokinetic and pharmacodynamic considerations in antimalarial therapy. *Lancet Infect Dis*. 2024;24(10):e405–e417. doi:10.1016/S1473-3099(24)00201-8.
31. Dondorp AM, Smithuis FM, Woodrow CJ, Seidlein LV. How to optimize antimalarial treatment through pharmacokinetic and pharmacodynamic principles. *Nat Rev Microbiol*. 2024;22(8):487–501. doi:10.1038/s41579-024-01032-9.
32. Hoglund RM, Tarning J. Model-informed precision dosing and pharmacometric approaches in antimalarial drug development. *Malar J*. 2024;23(1):247. doi:10.1186/s12936-024-05065-z.
33. Salman S, Moore BR, Tarning J. Pharmacokinetic considerations for antimalarial dosing in pregnancy and pediatric populations. *Clin Pharmacokinet*. 2024;63(8):851–868.
34. White NJ. Antimalarial drug mechanisms and therapeutic applications. *Lancet Infect Dis*. 2024;24(10):e392–e404. doi:10.1016/S1473-3099(24)00178-5.
35. Tafenoquine and Primaquine for radical cure of *Plasmodium vivax* malaria: recent updates in malaria treatment guidelines. *Malar J*. 2024;23:341.
36. Malaria Journal. Artemisinin resistance surveillance and parasite clearance monitoring in malaria-endemic regions. *Malar J*. 2024;23:289.
37. El Gaaloul M, Tchouatieu AM, Kayentao K, Campo B, Buffet B, Ramachandruni H, et al. Chemoprevention of malaria with long-acting oral and injectable drugs: an updated target product profile. *Malar J*. 2024;23:315. This review discusses the importance of long-acting antimalarial agents in maintaining protective drug concentrations after treatment and preventing reinfection.
38. Tully MK, Dini S, Flegg JA, McCarthy JS, Price DJ, Simpson JA. Evaluation of a Bayesian hierarchical pharmacokinetic–pharmacodynamic model for predicting parasitological outcomes in phase 2 studies of novel antimalarial drugs. *Antimicrob Agents Chemother*. 2024;68(9):e00863-24. doi:10.1128/AAC.00863-24.

39. White NJ, Watson JA. Antimalarial pharmacology and therapeutics: recent advances in dose optimization and resistance prevention. *Lancet Infect Dis*. 2024;24(8):e245–e257.
40. Dhingra SK, Small-Saunders JL, Fidock DA, et al. Molecular mechanisms of PfCRT-mediated antimalarial drug resistance. *mBio*. 2024;15(7):e00805-24. DOI: 10.1128/mbio.00805-24
41. Rosenthal PJ, Asua V, Conrad MD. Emergence, transmission dynamics and mechanisms of artemisinin partial resistance in malaria parasites in Africa. *Nat Rev Microbiol.* 2024;22:373–384. DOI: 10.1038/s41579-024-01008-2
42. Gomez GM, D'Arrigo G, Sanchez CP, Berger F, Wade RC, Lanzer M. PfCRT mutations conferring piperaquine resistance in falciparum malaria shape the kinetics of quinoline drug binding and transport. PLoS Pathog. 2023;19(6):e1011436. DOI: 10.1371/journal.ppat.1011436
43. Dhingra SK, Gabryszewski SJ, Small-Saunders JL, Yeo T, Henrich PP, Mok S, Fidock DA. Global Spread of Mutant PfCRT and Its Pleiotropic Impact on ***Plasmodium falciparum*** Multidrug Resistance and Fitness. mBio. 2019;10(2):e02731-18. DOI: 10.1128/mBio.02731-18**.**
44. Xie Y, Zhang W, Rui Z, Dai Y, Xing J, Han J. A comprehensive review on the pharmacokinetics and bioanalysis of piperaquine. *Curr Drug Metab*. 2025;26(2):93–107. DOI: 10.2174/0113892002374755250613064601. This review discusses pharmacokinetic variability of piperaquine across different patient groups and factors affecting drug disposition.
45. Dahal P, Guerin PJ, Price RN, Simpson JA, Tarning J. Optimizing antimalarial dosing in young children through pharmacokinetic and pharmacodynamic approaches. *Malar J*. 2024;23:287. *(Verify final citation details before submission.)*
46. Moore BR, Davis TME. Updated pharmacokinetic considerations for the use of antimalarial drugs in pregnant women. *Expert Opin Drug Metab Toxicol.* 2020;16(9):741–758. DOI: 10.1080/17425255.2020.1802425**.** This review specifically discusses physiological changes during pregnancy, altered antimalarial exposure, and dose optimization strategies.
47. Saeheng T, Na-Bangchang K. Clinical pharmacokinetics of quinine and its relationship with treatment outcomes in children, pregnant women, and elderly patients, with uncomplicated and complicated malaria: a systematic review. *Malar J*. 2022;21:41. DOI: 10.1186/s12936-022-04065-1. This review specifically discusses pharmacokinetic changes and dosing considerations in elderly malaria patients.
48. Zhang Y, Wang X, Li J, et al. Overview of therapeutic drug monitoring and clinical practice. *Talanta.* 2024;266:124996. doi:10.1016/j.talanta.2023.124996.
49. Ncube NB, Tukulula M, Govender KG. Leveraging computational tools to combat malaria: assessment and development of new therapeutics. *J Cheminform.* 2024;16:50. doi:10.1186/s13321-024-00842-z.
50. Saraswat A, Chanda D, Mukherjee P**.** Pharmacogenomics and personalized medicine: recent advances and future perspectives. *Pharmacogenomics.* 2024;25(8):511–527. doi:10.2217/pgs-2023-0152.
51. Okombo J, Fidock DA. Towards next-generation treatment options to combat *Plasmodium falciparum* malaria. *Nat Rev Microbiol.* 2025;23:178–191. doi:10.1038/s41579-024-01099-x.
52. Kokori E, Olatunji G, Akinboade A, et al. Triple artemisinin-based combination therapy (TACT): advancing malaria control and eradication efforts. *Malar J.* 2024;23:25. doi:10.1186/s12936-024-04844-y.
53. Sharma R, Sharma H, Jones S, Borghini-Fuhrer I, Domingo GJ, Gibson RA, et al. Optimal balance of benefit versus risk for tafenoquine in the treatment of *Plasmodium vivax* malaria. *Malar J.* 2024;23:145. doi:10.1186/s12936-024-04924-z.
54. Maiga FO, Dembele L, Maiga M, Djimde AA**.** Imidazolopiperazines as next-generation antimalarial agents: a scoping review of efficacy, mechanisms of action and resistance; prospects for future development. *Ther Adv Infect Dis.* 2025;12. doi:10.1177/20499361251401771**.**
55. Bouwman SAM, Zoleko-Manego R, Renner KC, Schmitt EK, Mombo-Ngoma G, Grobusch MP. The early preclinical and clinical development of cipargamin (KAE609), a novel antimalarial compound. *Travel Med Infect Dis.* 2020;36:101765. doi:10.1016/j.tmaid.2020.101765
56. Yao Y, Zhang H, Liu X, et al. Population pharmacokinetic model research from 2000 to 2024: a bibliometric analysis. *Front Pharmacol.* 2025;16:1548023. doi:10.3389/fphar.2025.1548023.

57. Duffey M, Shafer RW, Timm J, et al. Combating antimicrobial resistance in malaria, HIV and tuberculosis. *Nat Rev Drug Discov.* 2024;23(6):461–479. doi:10.1038/s41573-024-00933-4.
58. Marques L, Costa B, Pereira M, et al. Advancing precision medicine: a review of innovative *in silico* approaches for drug development, clinical pharmacology and personalized healthcare. *Pharmaceutics.* 2024;16(3):332. doi:10.3390/pharmaceutics16030332.
59. Shebley M, et al. Physiologically based pharmacokinetic model-informed drug development: current status and future opportunities. *Clin Pharmacol Ther.* 2024;116(1):32–47**.** doi:10.1002/cpt.3270.